Session Details
Poster Oral Presentation 3
Fri. Jul 11, 2025 1:00 PM - 1:45 PM JST
Fri. Jul 11, 2025 4:00 AM - 4:45 AM UTC
Fri. Jul 11, 2025 4:00 AM - 4:45 AM UTC
Room Ⅶ (Makuhari Messe International Conference Room)(Makuhari Messe International Conference Room) 3
[PO-023]Efficacy and Safety of Different Doses of Adalimumab in Crohn's Disease: A Multicenter Cohort Study in Infliximab-Naïve and Infliximab-Exposed Patients
*Zhaoyuan Xu1,2,3, Xiang Peng1,2,3, Min Zhang1,2,3, Min Zhi1,2,3 (1. Department of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-Sen University, 2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-Sen University, 3. Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University)
[PO-024]Predictive Factors in the early stage of Carotegrast Methyl treatment for Clinical Remission in Patients with Ulcerative Colitis
*Makoto Furuya1, Ken Takeuchi1, Keita Saito1, Kiichirou Yoza1, Ken Yonezawa1, Yukihiro Hamahata2 (1. Department of Gastroenterology, Tsujinaka Hospital Kashiwanoha, 2. Department of Colorectal Surgery, Tsujinaka Hospital Kashiwanoha)
[PO-025]Biologic therapy for the management of budesonide refractory/dependent microscopic colitis
*Lydia Crothers-Stomps1, Pradeep Kakkadasam Ramaswamy1, Waled Mohsen1, John Edwards1 (1. Gold Coast University Hospital, Queensland, Australia)
[PO-026]Long-Term Treatment Persistence, Safety, and Loss of Response to First Anti-Tumor Necrosis Factor (TNF) Therapy in Pediatric and Adolescent Patients with Inflammatory Bowel Disease
*Serina Haruyama1, Reiko Kunisaki1, Daisuke Nishida1, Kazuki Kurimura1, Yuki Koyo1, Yuki Suga1, Yoshinori Nakamori1, Risa Onizawa1, Ayane Sugino1, Sumiwo Mimuro1, Reina Onaka1, Takumi Fujii1, Shun Suyama1, Masaki Takeuchi1, Maho Kubota1, Yujiro Hatakeyama1, Wakana Tominaga1, Rina Agawa1, Kyohei Yamashita1, Haruto Hiraga1, Naoki Ikegami1, Yuto Tsuru1, Yurika Nishikawa1, Mizuki Tatsuno1, Katsuki Yaguchi1, Kota Imanishi1, Kenichiro Toritani1, Hideaki Kimura1, Shin Maeda2 (1. Inflammatory Bowel Disease Center, Yokohama City University Medical Center, 2. Department of Gastroenterology, Yokohama City University, Graduate School of Medicine)
[PO-027]Identification of risk factors for disease progression in ulcerative colitis and assessment of biologic treatment based on risk stratification
*Pingxin Zhang1, Chuhan Zhang1, Zhirong Zeng1, Baili Chen1, Yao He1, Ren Mao1, Yun Qiu1, Minhu Chen1 (1. Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University)
[PO-028]Impact of the third lumbar skeletal muscle mass index on drug therapy of patients with inflammatory bowel disease
*Linglin Tian1, Yang Liu, Changxing Fang, Ying Qiao1 (1. Department of Gastroenterology, First Hospital of Shanxi Medical University)
[PO-029]Persistence of biologic therapy in patients with inflammatory bowel disease: A single center cohort study
*Kwangwoo Nam1, Jongbeom Shin2 (1. Dankook University Hospital, 2. Inha University Hospital)
[PO-030]Clinical and Proteomic Predictors of Primary Response to Infliximab in Crohn’s Disease with Small Bowel Involvement: A Pilot Study in China
*Yaqing Bai1,2, Yinghao Sun1, Xiaowei Xue1, Gechong Ruan1, Weiyang Zheng1, Hui Xu1, Yujia Zhang1, Yiming Zhang1, Xiaoyin Bai1, Hong Yang1 (1. Peking Union Medical College Hospital, 2. Chinese Academy of Medical Sciences & Peking Union Medical College)
[PO-031]A study on predicting the efficacy of infliximab for Crohn's disease using pre-treatment endoscopic images.
*Ruidong Chen1, Qi Liu1, Qing Xu2, Junjian Sun2, Qiming Fu3, Mingxiang Wei4, Wen Tang1, Hongjie Zhang2 (1. The Second Affiliated Hospital of Soochow University, 2. The First Affiliated Hospital with Nanjing Medical University, 3. Suzhou University of Science and Technology, 4. The Affiliated Suzhou Hospital of Nanjing Medical University)
[PO-032]The Efficacy of Upadacitinib in Anti-TNF-Refractory Intestinal Behçet's Disease
Juan Du1, Jiaoying Lu2, Yiyuan Fang2, *Chunxiao Chen1 (1. First Affiliated Hospital of Zhejiang University School of Medicine, 2. School of Medicine, Zhejiang University)
[PO-033]Ustekinumab for Intestinal Behçet's Disease: The First Cohort with a Novel Therapy
*Hongsheng Yang1, Miao Li1, Zhaopeng Huang1, Xiang Gao1, Pinjin Hu1 (1. The Sixth Affiliated Hospital, Sun Yat-sen University)